Effects of Empagliflozin and Lifestyle Intervention on Improving Body Weight and Other Metabolic Parameters in Atypical Antipsychotics-treated Patients with Schizophrenia Spectrum Disorders-A Double-blind Randomized Placebo-controlled Trial
Abstract
Abstract Background and Hypothesis Patients with schizophrenia spectrum disorders have elevated cardiovascular risk with obesity and deranged metabolic profiles associated with antipsychotic usage, bearing significant tolls on chronic morbidity and mortality. The present study aims to evaluate the efficacy and tolerability of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in improving weight control and metabolic profile in atypical antipsychotics-treated patients with schizophrenia spectrum disorders. Study Design This double-blind, randomized, placebo-controlled trial studied overweight or obese adults with schizophrenia spectrum disorders (non-diabetic or pre-diabetic) who were taking atypical antipsychotics. Participants recruited from a specialist clinic of a regional public service were randomized to receive empagliflozin or placebo for 16 weeks, in combination with standardized lifestyle intervention through psychoeducation. The primary outcomes were changes in body weight and body mass index (BMI). Changes in other metabolic parameters were examined as secondary outcomes. Linear mixed models were used to study the differences in outcomes between the active and placebo arms. Results Of the 52 patients undergoing randomization, the SGLT2i group had significant reductions in body weight (−1.53 kg; 95% CI, −2.60 to −0.47), BMI (−0.53 kg/m2; 95% CI, −0.91 to −0.15), fasting glucose (−0.40 mmol/L; 95% CI, −0.65 to −0.15), and glycated hemoglobin A1c (−0.11%; 95% CI,…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 52 participants or records.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.